Ozon Pharmaceuticals

Ozon Pharmaceuticals is a Russian manufacturer of pharmaceuticals. The product range is represented in all pharmaceutical niches: traditional low molecular weight pharmaceuticals, production of highly toxic drugs against oncology and complex science-intensive drugs in the field of biotechnology. It produces more than 350 items of finished pharmaceuticals, with an annual output of about 5 billion units.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ozon Pharmaceuticals balance sheet

Report period2021 2022 2023 Q3 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ozon Pharmaceuticals cash flows

Report period2021 2022 2023 Q3 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ozon Pharmaceuticals multipliers

Report period2021 2022 2023 Q3 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Ozon Pharmaceuticals profitability

Report period2021 2022 2023 Q3 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ozon Pharmaceuticals assets
Ozon Pharmaceuticals cash flows
Ozon Pharmaceuticals dividends
0.52%

Ozon Pharmaceuticals dividend policy

The criterion for dividend payment is the Net Debt / EBITDA ratio. The dividend policy envisages the following scenarios: Net Debt / EBITDA > 3x - no dividends are paid; 2x < Net Debt / EBITDA ≤ 3x - at least 15% of Net Profit; 1x < Net Debt / EBITDA ≤ 2x - at least 25% of Net Profit; 0x < Net Profit / EBITDA ≤ 1x - at least 35% of Net Profit, but not more than 100% of free cash flow; Net Profit / EBITDA = 0x - at least 50% of Net Profit, but not more than 100% of free cash flow.

Ozon Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
OZPH:RMOzon PharmaceuticalsCommon shareRUB 0.02RU000A109B25RUB 60.34

Ozon Pharmaceuticals bonds

NameIssue sizePriceYield
Ozon 001P-01 (RUB)1,000,000 pcs.94.44%15.89%
Ozon 001P-02 (RUB)700,000 pcs.92.1%17.12%
Share capital structure of Ozon Pharmaceuticals
Ozon Pharmaceuticals news
18.02.2025
Ozon Pharmaceuticals' sales in 2024 amounted to 321 mln packs of pharmaceuticals, up 13% year-on-year. Major growth in sales in volume terms came from the government procurement segment, where more than 93.7 million packs were sold during the year, up 44% year-on-year in 2023. Retail sales grew by 4% to 227.5 million packs.
30.01.2025
Ozon Pharmaceuticals completed the next stage of construction of the Ozon Medica production site in the special economic zone of Togliatti. Monolithic works in the main production building have been completed, and the foundation for the installation of roofing and walls has been prepared. During 2025 it is planned to complete general construction and finishi...
24.12.2024
Ozon Pharmaceuticals has already shipped more than 1 million packs of the new generic drug Cruoxaban to distributors since December 5. Drug is sold both in the retail pharmacy segment and through the government procurement system to supply hospitals and clinics.
18.12.2024
Shareholders of Ozon Pharmaceuticals approved dividends for 9 months 2024 in the amount of ₽0.18 per ordinary share. The last day of purchase of securities to receive dividends is December 26, 2024. Dividend yield may amount to 0.6%.
General information
Company nameOzon Pharmaceuticals
Tags#pharmacy, #biotechnology, #ipo2024
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressRF, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Mailing address445351, Samarskaya oblast, g. Zhigulevsk, ul. Gidrostroiteley, d. 6
Websiteozonpharm.ru
Information disclosuree-disclosure.ru